使用北印度私营部门的一家医院的癌症登记簿（HBCR）数据，我们提供了儿童癌症患者的总体生存率（OS）和事件自由生存率（EFS）。我们的HBCR登记了从2013年3月1日至2021年7月31日之间所有新诊断的儿童（年龄＜18岁）癌症患者。利用Kaplan-Meier方法计算了3年和5年的OS（死亡为事件），EFSc（死亡，进展/复发为事件）和EFSa（死亡，进展/复发，放弃治疗为事件）。进行回归分析以了解它们与人口统计学、诊断和治疗变量的关联。共登记了705名新诊断的儿童癌症患者（36.2％为女性）。常见的癌症类型为白血病（26％）、中枢神经系统肿瘤（20％）和骨肿瘤（16％）。202名患者（28.6％）在中位随访时间为1.95年（范围0-8.14年）时发生了事件，其中包括23名（3.3％）放弃治疗的患者。3年的OS、EFSc和EFSa分别为70.8％、64.4％和63.6％，相应的5年的OS、EFSc和EFSa分别为66.0％、58.6％和57.5％。在年龄组、性别、国籍以及是否在其他地方开始了癌症治疗等方面没有显著差异。通过主要和扩展的国际儿童癌症分类类别，OS、EFSa和EFSc有显着差异（P＜0.001）。我们提供了印度儿童癌症最新的登记数据，同时也是EFS的首次估计。

Using data from a hospital-based cancer registry (HBCR) in the private sector in Northern India, we provide overall survival (OS) and event-free survival (EFS) for childhood cancer patients.All newly diagnosed childhood (age <18 years) cancer patients in our HBCR registered between March 1, 2013 till July 31, 2021 were eligible. 3-year and 5-year OS (death was an event), EFSc (death, progression/relapse was an event), and EFSa (death, progression/relapse, abandonment of treatment was an event) were calculated using the Kaplan-Meier method. Regression analysis was done to see their association with demographic, diagnostic and treatment variables.705 newly diagnosed children (36.2% female) with cancer were registered. Common cancers were leukemias (26%), CNS tumors (20%) and bone tumors (16%). 202 (28.6%) had experienced an event at median follow up of 1.95 years (range 0-8.14 years), which included 23 (3.3%) who abandoned treatment. The 3-year OS, EFSc, EFSa were 70.8%, 64.4% and 63.6%, respectively. Correspondingly, 5-year OS, EFSc, EFSa were 66%, 58.6% and 57.5%, respectively. There was no significant difference by age group, gender, nationality, and if cancer directed treatment initiated elsewhere. The OS, EFSa and EFSc by the main and the extended International Childhood Cancer Classification categories varied significantly (P<0.001).We add more recent registry-based OS data on childhood cancer in India and present the first estimates on EFS.